Laboratory studies of molecular genetical interventions in oncology by Waardenburg, Robert Cornelis Adrianus Maria van
  
 University of Groningen
Laboratory studies of molecular genetical interventions in oncology
Waardenburg, Robert Cornelis Adrianus Maria van
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
1997
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Waardenburg, R. C. A. M. V. (1997). Laboratory studies of molecular genetical interventions in oncology.
s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
\ . J . , .Ma r t i n i ,  I .A . ,
;ptatrn resistance in)89.
bacteriophage T4.




e.  J.  Bio l .  Chem.
W.J. ,  Wi l lemse,
one S-transferase
70-78,  199s.
Y. ,  and Clausen,
nor regu;ated by




With the wide spread availability of molecular genetic techniques, thorough studies
into various genetic aspects of the malignant phenotype 
.have become possible. They
revealed that accumulation of genetic defects are responsible for the development of normal
cells into cancer cells. Among the genetic defects related to cancer are,
activation/amplification of oncogenes, suppression/mutation of tumor suppressor genes and
activation of transporter proteins. Furthermore, with the availability of the molecular
genetic techniques, development of new genetic anti-cancer treatments are possible, either
alone or in combination with existing treatments. Among the existing treatments
chemotherapy plays an important role. At the moment clsplatin (cDDP) alone or in
combination with other anti-cancer agents, such as anthracyclines, is successfully used to
treat cancer patients. Most solid tumors are initially responding, however, after initial
treatment many patients relapse, often due to acquired drug resistance. To gain insight in
the molecular genetic mechanisms responsible for drug resistance, is a major goal in cancer
research.
The review in chapter I describes the mechanisms of drug resistance in lung cancer.
Resistance to chemotherapeutic drugs is also a major problem in the treatment of patients
with this tumor. Mechanisms responsible fbr drug resistance include the multi-drug
resistance (MDR) phenotype, detoxification in general and the control of cell death. The
Íïrst part of the review describes the MDR-phenotype that oÍten has a multifactorial origin.
Common causes are: activation of drug transporter proteins, such as P-glycoprotein
(MDRl-gene) and the multidrug resistance related protein (MRP), together with reduced
topoisomerase II expression. In addition, increased etoxification mechanisms can be Íbund,
in which Íbr example abundance of thiol-groups (SH-groups) fiom glutathione (GSH) and
metallothioneins are involved. Finally, the control of cell death is discussed, in particular
the role of the nrmor suppressor gene p53.
In chapter 2 gene transfer methods and their applications in cancer research are
discussed together with their impact on cancer treatment. In this review transfection
techniques such as calcium phosphate co-precipitation, electroporation, lipofection and viral
mediated gene transfèr are described.
The molecular basis for resistance to cDDP and adriarnycin (Adr, an anthra-cycline)
is poorly understood. One of the genetic alterations observed in SCLC is amplification and
overexpression of the c-myc oncogene which might form a basis Íbr resistance. ThereÍbre,
the eÍïècts of c-myc oncogene down-regulation on drug resistance in hurnan small cell lung
carcinoma (SCLC) cell l ines is characterized in chapter 3 and 4.In chapter 3, the relation
between c-myc and cDDP as well as Adr resistance, was analyzed. Tl.ris was realized by
down-regulation of endogenously expressed c-myc in the human SCLC cell line GLC, and
its cDDP and Adr resistant sublines (GLC.-cDDP and GLCo-Adr). In this chapter an
antisense c-myc DNA approach was applied and down-regulation was achieved by inhibition
of translation together with degradation of the mRNA strand caused by hybridization of the
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antisense DNA oligonucleotide. In this study, an unmodified antisense oligodeoxynucleotide
complementary to the first 5 codons of the c-myc mRNA in a serum free cuiture medium
was used. Pre-incubation with 15 pM antisense c-myc, reduced c-myc protein expression
and induced 30-35% growth inhibition in all three cell lines. Furthermore, an increased
cDDP sensitivity was observed only in GLC.-cDDP cells. This change was not mediated by
changes in cell cycle distribution. No effect on Adr sensitivity in all three cell lines was
observed. These findings suggest that c-myc plays a role in cDDP resistance, by effects
other than those on cell cycle distribution. A limitation of this antisense approach is the poor
cellular uptake of the oligonucleotide. Additionally, the absence of universal antisense
targets sites/domains in the mRNA molecule is a drawback for development of new
antisense sequences and their functionality.
Another antisense c-myc approach was used in chapter 4 to study further the relation
between c-myc expression and drug resistance in the cDDP resistant SCLC cell line.
GLC.cDDP. This approach used the formation of a mRNA/AS-RNA complex to inhibit
lranslation and induce degradation of the c-myc mRNA. For this GLCTcDDP cells were
stably transfected with either an inducible antisense c-myc (AS) or control (C) expression
vector resulting in respectively, the subclones GLCTcDDP/AS and GLC.- cDDP. PCR and
RT-PCR analysis showed the integration and activation of the dexamethasone (dex)
inducible MMTV-LTR promoter linked to the complete AS c-myc fragment in
GLC,,cDDP/AS cells but not in GLC'cDDP/C cells. Dex-induced AS c-myc RNA resulted
tn a 50% growth inhibit ion during the first 48 h which declined to 25% at 12 h. In addition,
the cloning etïicacy was reduced by 36% and a 2-ibld induction of apoptosis within 24 h in
GLC.cDDP/AS cells was observed. Dex treatment did not affect the proliÍèration,
clonogenicity and induction of apoptosis in the control cell lines. Furthermore, AS c-myc
RNA expression caused an 1.4-fold increased cDDP sensitivity but ncl change in Adr or
vincristine sensitivity in GLC4cDDP/AS. These results indicate that AS c-myc RNA
expression causes inhibition of cell proliferation, induces apoptosis, reduces clonogenicity
and interÍères with cDDP sensitivity but not with Adr or vincristine sensitivity. A general
drawback Íbr regulated transcription of exogenously introduced genes. is the absence of a
strong inducible promoter for eucaryotic cells. The available inducible promoters can not
boost transcription to produce Íbr example antisense RNA rnolecules in abundance relative
to the endogenously expressed mRNA molecules.
Both antisense c-myc strategies were employed in chapter 5, describing the influence
of c-myc modulation on cell differentiation stanrs of respectively, GLC. and GLC.cDDP
cells. Basic ditÍerentiation status showed that the neuro-endocrine marker (CD57) was
decreased together with an increased vimentin expression in GLC,,cDDP compared to
GLC,*. Co-culture of antisense c-myc DNA oligonucleotide showed no effect on expression
of vimentin, CD15 (a myeloid marker), CD57 and VLA-cr4 (an extracellular adhesion
marker) in GLC. and in GLC.cDDP only the CD57 expression was decreased. Expression
of antisense c-myc RNA did not alter the expression of the tested antigens in
GLC,cDDP/AS cells. Vimentin is considered to be a marker of resistance with no direct
involvement in resistance.
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acquired mitoxantrone resistant human SCLC cell line, GLCr-MITO. In this study a PCR-
based cDNA subtraction method was used to screen the difference in gene expression
between the mitoxantrone resistant and sensitive cell line. The GLC.-MITO minus GLC.
subtraction showed a different amplicon laddering compared to the reversed subtraction.
Nineteen amplicons of the GLC'-MITO minus GLC. subtraction were cloned and Íbur
arbitrarily chosen amplicons were sequenced. Sequence similarity analysis revealed that
amplicon Ml was similar to several expressing sequenced tags (ESTs) with unknown
protein or function. M3 showed similarity with a putative methyltransferase from
Saccharomyces cerevísiae, amplicon M7 was similar with the Mus musculus FIN14 mRNA
in the 3' non-coding region. The amplicon M9 demonstrated similarity with the mouse
voltage dependent anion channel 3 protein. For further analysis of these ESTs and the other
cloned amplicons, the complete cDNA fragment must be isolated. However, this method
proved to be a very sensitive tool for the identification of changes in gene expression
between two cell lines with a very low Íalse/positive background.
In chapter 7 and 8 three hot spot mutant p53 genes, with mutations in amino acid
ll5, 248 or 273, were expressed in a wild{ype p53 background of the 42180 ovarian
tumor cell line. The influence of these mutants, wild-type p53 and the empty control vector,
on drug resistance and gene expression were characterized. Only the mutant 273 showed a
2-3 fold decreased cDDP, paclitaxel and 5-Íluorouracil (5-FU) sensitivity together with a 6-
7 fold decreased teniposide and mitoxantrone sensitivity in comparison to the A2780
parental cell line. Furthermore, only the mutant 248 showed a2-3 fold decreased sensitivity
for teniposide and mitoxantrone. Expression of Bcl-2 was reduced in all mutant p53
expressing cell lines. In none of the p53 transfected cell lines were changes found in gene
expression levels of p53 regulated pathway genes, such as BAX, WAF, MDM2 and PARP
compared to A2780. Mutant 273 showed a decreased protein levels of topoisomerase IIc
and IIB while mutant 248 showed only a slight reduction of these proteins.
Similar levels of DNA-cisplatin adducts were detected in various transf'ected cell lines, and
we fbund only in mutant 213 a reduced cDDP and teniposide induced apoptosis. This
reduced apoptosis coincided with altered cell cycle distribution after cDDP as well as
teniposide exposure. We conclude that specific mutant p53 gene expression, can induce
resistance to cDDP, paclitaxel, 5-FU and several topoisomerase II inhibitors.
Conclusion and perspectives
The results that were obtained in this thesis, showed that oncogenes (e.g. c-myc) are not
only of importance for the regulation of cell growth but that they can also play a role in the
induction or maintenance of resistance to specific anti-cancer agents. Additionally, it was
shown that mutated tumor suppressor genes (e.g. p53) Íavored cell survival, during or after
drug exposure while the wild-type led to ceil death. Differential gene screening technology
can become an important application, to detect and identiÍy novel drug resistance related
Írenes. in future studies.
t17
The studies described in this thesis show some of the possibilities of the applicationof specific molecular genetic techniques in oncology. The results of the oescribed and othernewly developed molecular techniques might increase the insight in the genetic responsemechanisms of a malignant and drug resistint phenotype uta trrEr.uy^possibly conrribute tothe cure of cancer patients.
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